Brief: Herantis Pharma announces results from phase 2 Cis-UCA Dry Eye study
03/06/2015 06:01
June 3 (Reuters) - Herantis Pharma Oyj HRTIS.HE :
* Completed its initial analysis of results of its phase 2 clinical study of Cis-UCA in Dry
Eye disease
* Cis-UCA did not show statistically significant improvements in two co-primary endpoints
for treatment of signs and symptoms of dry eye
* Statistically significant efficacy was seen in some secondary endpoints
* Cis-UCA was safe and as well tolerated as placebo
Source text for Eikon: ID:nHUG5gKg9J
Further company coverage: HRTIS.HE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))